WO2012012510A3 - Gene expression profiling for the identification of lung cancer - Google Patents

Gene expression profiling for the identification of lung cancer Download PDF

Info

Publication number
WO2012012510A3
WO2012012510A3 PCT/US2011/044648 US2011044648W WO2012012510A3 WO 2012012510 A3 WO2012012510 A3 WO 2012012510A3 US 2011044648 W US2011044648 W US 2011044648W WO 2012012510 A3 WO2012012510 A3 WO 2012012510A3
Authority
WO
WIPO (PCT)
Prior art keywords
identification
gene expression
lung cancer
expression profiling
copd
Prior art date
Application number
PCT/US2011/044648
Other languages
French (fr)
Other versions
WO2012012510A2 (en
Inventor
Karl Wassmann
Danute M. Bankaitis-Davis
Kathleen Storm
Lisa Siconolfi
Original Assignee
Dxterity Diagnostics
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Dxterity Diagnostics filed Critical Dxterity Diagnostics
Priority to EP11810327.4A priority Critical patent/EP2596131A4/en
Publication of WO2012012510A2 publication Critical patent/WO2012012510A2/en
Publication of WO2012012510A3 publication Critical patent/WO2012012510A3/en

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
    • C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
    • C12Q1/6876—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes
    • C12Q1/6883—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material
    • C12Q1/6886—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material for cancer
    • G—PHYSICS
    • G16—INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR SPECIFIC APPLICATION FIELDS
    • G16B—BIOINFORMATICS, i.e. INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR GENETIC OR PROTEIN-RELATED DATA PROCESSING IN COMPUTATIONAL MOLECULAR BIOLOGY
    • G16B25/00—ICT specially adapted for hybridisation; ICT specially adapted for gene or protein expression
    • G16B25/10—Gene or protein expression profiling; Expression-ratio estimation or normalisation
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q2600/00—Oligonucleotides characterized by their use
    • C12Q2600/158—Expression markers
    • G—PHYSICS
    • G16—INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR SPECIFIC APPLICATION FIELDS
    • G16B—BIOINFORMATICS, i.e. INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR GENETIC OR PROTEIN-RELATED DATA PROCESSING IN COMPUTATIONAL MOLECULAR BIOLOGY
    • G16B25/00—ICT specially adapted for hybridisation; ICT specially adapted for gene or protein expression

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Genetics & Genomics (AREA)
  • Physics & Mathematics (AREA)
  • Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Molecular Biology (AREA)
  • Biophysics (AREA)
  • Biotechnology (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Spectroscopy & Molecular Physics (AREA)
  • Theoretical Computer Science (AREA)
  • Zoology (AREA)
  • Immunology (AREA)
  • Medical Informatics (AREA)
  • Pathology (AREA)
  • Evolutionary Biology (AREA)
  • Analytical Chemistry (AREA)
  • Bioinformatics & Computational Biology (AREA)
  • Wood Science & Technology (AREA)
  • Oncology (AREA)
  • Microbiology (AREA)
  • Hospice & Palliative Care (AREA)
  • Biochemistry (AREA)
  • General Engineering & Computer Science (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)

Abstract

The invention provides gene models useful in the screening of at-risk patients for lung cancers including smokers with and without chronic obstructive pulmonary disease (COPD).
PCT/US2011/044648 2010-07-21 2011-07-20 Gene expression profiling for the identification of lung cancer WO2012012510A2 (en)

Priority Applications (1)

Application Number Priority Date Filing Date Title
EP11810327.4A EP2596131A4 (en) 2010-07-21 2011-07-20 Gene expression profiling for the identification of lung cancer

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US36633110P 2010-07-21 2010-07-21
US61/366,331 2010-07-21

Publications (2)

Publication Number Publication Date
WO2012012510A2 WO2012012510A2 (en) 2012-01-26
WO2012012510A3 true WO2012012510A3 (en) 2012-05-24

Family

ID=45497433

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/US2011/044648 WO2012012510A2 (en) 2010-07-21 2011-07-20 Gene expression profiling for the identification of lung cancer

Country Status (2)

Country Link
EP (1) EP2596131A4 (en)
WO (1) WO2012012510A2 (en)

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP6240804B1 (en) * 2017-04-13 2017-11-29 大▲連▼大学 Filtered feature selection algorithm based on improved information measurement and GA
CN110699457B (en) * 2019-10-30 2022-11-25 深圳瑞科生物科技有限公司 Primer group and kit for detecting lung cancer

Family Cites Families (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7871774B2 (en) * 2005-01-31 2011-01-18 Digital Genomics Inc. Markers for the diagnosis of lung cancer
EP2087140A2 (en) * 2006-11-13 2009-08-12 Source Precision Medicine, Inc. Gene expression profiling for identification, monitoring, and treatment of lung cancer

Non-Patent Citations (4)

* Cited by examiner, † Cited by third party
Title
GONZALEZ-ARRIAGA, P. ET AL.: "Polymorphism +17C/G in matrix metalloprotease MP8 decreases lung cancer risk.", BMC CANCER, vol. 8, no. 378, 19 December 2008 (2008-12-19) *
OCAK, S. ET AL.: "High-throughput molecular analysis in lung cancer: insights into biology and potential clinical applications.", EUR. RESPIR. J., vol. 34, no. 2, August 2009 (2009-08-01), pages 489 - 506, XP055072660 *
OHRI, C. M. ET AL.: "Chemokine receptor expression in tumor islets and stroma in non-small cell lung cancer.", BMC CANCER, vol. 10, no. 172, 29 April 2010 (2010-04-29), XP021075011 *
YIN, Z. ET AL.: "ERCC2, ERCC1 polymorphisms and haplotypes, cooking oil fume and lung adenocarcinoma risk in Chinese non-smoking females.", J. EXP. CLIN. CANCER RES., vol. 28, no. 153, 14 December 2009 (2009-12-14), XP021070230 *

Also Published As

Publication number Publication date
WO2012012510A2 (en) 2012-01-26
EP2596131A2 (en) 2013-05-29
EP2596131A4 (en) 2013-12-18

Similar Documents

Publication Publication Date Title
HK1252674A1 (en) Mirna fingerprint in the diagnosis of lung cancer
IL261348A (en) An isolated antibody or fragment thereof that binds cd100, for use in the treatment of an autoimmune disease, an inflammatory disease of cancer
HK1204062A1 (en) Lung cancer biomarkers and uses thereof
IL223295A0 (en) Lung cancer biomarkers and uses thereof
EP3607089A4 (en) Plasma based protein profiling for early stage lung cancer prognosis
HK1208501A1 (en) Method for the diagnosis, prognosis and treatment of lung cancer metastasis
LT2845593T (en) Pyridine and pyrazine derivative for the treatment of chronic obstructive pulmonary disease
HK1133802A1 (en) Methods of making reconstituted tobacco sheets
HK1213976A1 (en) Prediction of drug sensitivity of lung tumors based on molecular and genetic signatures
EP2250287A4 (en) Detection and prognosis of lung cancer
EP2411003A4 (en) Use of artemisinin derivatives for the treatment of asthma and chronic obstructive pulmonary disease (copd)
WO2012125712A3 (en) Lung tumor classifier for current and former smokers
HK1197274A1 (en) Micro-rna biomarkers for identifying risk of and/or for diagnosing lung tumour and pharmaceutical compositions thereof / rna
EP2744919A4 (en) Gene signatures for lung cancer prognosis and therapy selection
WO2012135841A3 (en) Emt signatures and predictive markers and method of using the same
HK1202619A1 (en) Method for aiding in the diagnosis and therapy of asthma and lung cancer
GB2536374B (en) Biomarkers useful for detection of types, grades and stages of human breast cancer
EP3610260A4 (en) Biomarker combinations for monitoring chronic obstructive pulmonary disease and/or associated mechanisms
IL228579A0 (en) Methods for predicting and improving the survival of gastric cancer patients
WO2013049152A3 (en) Methods for evaluating lung cancer status
EP2958999A4 (en) Gene signatures for lung cancer prognosis and therapy selection
EP2406401A4 (en) Methods of identification, assessment, prevention and therapy of lung diseases and kits thereof including gender-based disease identification, assessment, prevention and therapy
EP2921858A4 (en) Method for obtaining data that are useful for the diagnosis, prognosis and classification of patients with chronic obstructive pulmonary disease (copd) and/or lung cancer
WO2012012510A3 (en) Gene expression profiling for the identification of lung cancer
EP2710379A4 (en) Methods for determining the likelihood of survival and for predicting likelihood of metastasis in cancer patients

Legal Events

Date Code Title Description
121 Ep: the epo has been informed by wipo that ep was designated in this application

Ref document number: 11810327

Country of ref document: EP

Kind code of ref document: A2

NENP Non-entry into the national phase

Ref country code: DE

WWE Wipo information: entry into national phase

Ref document number: 2011810327

Country of ref document: EP